Introduction: Burnout among nurses has emerged as a critical issue in healthcare and is gaining considerable attention due to its profound negative effects. The pervasive nature and significant effects that burnout might hold underscore the crucial need to assess this issue and its contributing factors among nurses. However, there is an evident gap in research precisely addressing this issue among nurses working in private hospitals in the Gulf Region. Objective: This study aims to assess the prevalence and associated factors of burnout among nurses at private tertiary hospitals in Saudi Arabia and the United Arab Emirates. Method: This is a cross-sectional study, and the data were collected by an electronic self-administered survey. This multicenter study involved a sample of 616 nurses and was performed in six different private tertiary care hospitals which belong to the largest private healthcare group in the Gulf Region. The Maslach Burnout Inventory—Human Services Survey was utilized to assess burnout levels. Results: The study's results revealed that the overall burnout level was 67.2%. Notably, 82.8% of the participants were identified as having high Emotional Exhaustion (EE), 56.8% for high Depersonalization (DP), and 44.6% for low Personal Accomplishment (PA). The mean score for the EE dimension was 36.79 ± 10.34, the DP dimension was 13.91 ± 6.65, and the PA dimension had a mean score of 32.37 ± 7.73. Conclusion: The conclusions revealed a significant prevalence of burnout among nurses working within the private sector in Saudi Arabia and the United Arab Emirates. This underscores the persistent problem of burnout among nurses, which necessitates targeted interventions.

Background: Psoriasis, a chronic autoimmune condition, imposes significant burdens on patients’ well-being. While corticosteroid medications are commonly used, their prolonged use presents risks. Statins, known for their immunoregulatory and anti-inflammatory properties, have emerged as potential alternatives. Previous reviews indicated that statins might improve psoriasis symptoms but showed inconsistent results and lacked meta-analyses that generated pooled effect estimates. Therefore, this study addresses this gap by providing a comprehensive overview of the impact of statins on psoriasis severity and quality of life (QoL) for patients with psoriasis. Methods: A thorough search of four electronic databases (PubMed, Cochrane Central Register of Controlled Trials, Scopus, and Science Direct) was conducted for relevant studies published before April 2024. Results: Seven studies involving 369 patients were included. This meta-analysis showed a statistically significant reduction in PASI scores at week 8 with statin treatment (MD = −1.96, 95% CI [−3.14, −0.77], p = 0.001). However, no statistically significant difference was found between statins and placebo at week 12 (MD = 0.19, 95% CI [−0.18, 0.55]). Additionally, DLQI scores indicated a significant improvement in quality of life with statins compared to placebo (MD = −3.16, 95% CI [−5.55, −0.77]). Conclusions: Statins can improve disease severity and quality of life in psoriasis patients, suggesting the potential benefits of statin therapy. However, further research is needed to determine the optimal treatment duration, address outcome heterogeneity, and explore additional benefits such as cholesterol and triglyceride reduction.

Air pollution is a serious environmental factor associated with higher rates of illness and death from respiratory, cardiovascular, and other non-communica

Providing care for patients nearing the end of life who have advanced heart failure presents significant challenges, especially in emergency settings where the primary focus is on life-saving interventions. Exploring the perceptions of emergency department staff is essential for identifying barriers and improving care delivery in this critical context. A qualitative study was conducted in two hospitals in Saudi Arabia. Semi-structured interviews were completed with thirty emergency staff. A thematic analysis was used to identify the challenges in delivering care for patients nearing the end of life. Seven themes were identified: current practices for advanced heart failure patients, communication barriers, inadequate training in end-of-life care, limitations in emergency department design, heavy workloads, the influence of cultural and religious factors, and the importance of psychological and emotional support for patients and families. The findings highlight the need for structured training, cultural sensitivity, and improved environments to address these challenges. This study emphasizes the complexities of providing care for patients nearing the end of life in emergency settings. Addressing gaps in communication, training, and cultural competence is critical. Tailored strategies for Saudi Arabia's unique context are essential to enhance care for advanced heart failure patients.

Background: Obesity is a pathological condition and a major risk factor for dyslipidemia, type 2 diabetes, and non-alcoholic fatty liver disease. Recent research highlighted the association of non-invasive serum markers with these conditions but the clinical utility of ALT APRI in obesity and its relationship with dyslipidemia remain unexplored. Methods: We examined the association of ALT APRI in 165 non-diabetic adults stratified by BMI and serum lipid parameters. Results: Obese subjects had significantly higher APRI than lean subjects, with an area under the curve (AUC) of 0.65 (p = 0.019). Medians of APRI were significantly increased in subjects with high TG, TG/HDL, TC/HDL, and LDL/HDL and low HDL. Notably, all lipid parameters and ratios were significantly elevated in the highest APRI tertile, compared with patients in the lowest tertile. APRI was weakly yet significantly correlated with BMI (R² = 0.032, p = 0.022), HDL (R² = 0.071), TG/HDL (R² = 0.031), TC/HDL (R² = 0.063), LDL/HDL (R² = 0.072), and TyG index (R² = 0.081). While APRI only showed a discriminating capacity for HDL (AUC: 0.69, p = 0.003), TG/HDL (AUC: 0.63, p = 0.020), LDL/HDL (AUC: 0.68, p < 0.001), and TyG index (AUC: 0.65, p = 0.037), the highest diagnostic performance of APRI was observed with TC/HDL (AUC: 0.74, p < 0.001). Additionally, APRI was a risk factor for high TG (OR: 1.6, p = 0.028), low HDL (OR: 2.7, p = 0.0002), high TG/HDL (OR: 1.94, p = 0.0011), high TC/HDL (OR: 2.3, p < 0.0001), high LDL/HDL (OR: 2.2, p = 0.0001), and high TyG index (OR: 2.1, p = 0.008). Conclusions: Our findings argue for the role of APRI as a potential marker for obesity and dyslipidemia, which requires further confirmation in longitudinal studies.